表紙
市場調查報告書

CRO的全球市場:成長,趨勢,預測(2019∼2024年)

Contract Research Organization Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 824091
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
CRO的全球市場:成長,趨勢,預測(2019∼2024年) Contract Research Organization Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 115 Pages
簡介

CRO市場,預計2024年以7.2%的年複合成長率擴大。這個成長貢獻,研究開發費用的增加,研究開發活動的外包增加,臨床實驗數的增加等。

本報告提供全球CRO市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊彙整。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 推動市場的要素
    • 研究開發費用的增加
    • 臨床實驗數的增加
    • 使用了CRO服務的外包和降低成本的動向
  • 阻礙市場的要素
    • 熟練的專家不足
  • 波特五力分析

第5章 市場區隔

  • 各服務形式
    • 臨床研究服務
    • 早期開發服務
    • 實驗室服務
    • 諮詢服務
  • 各治療領域
    • 腫瘤
    • 感染疾病
    • 中樞神經系統疾病
    • 免疫疾病
    • 心血管疾病
    • 呼吸疾病
    • 糖尿病
    • 其他
  • 各終端用戶
    • 製藥公司、生物醫藥品企業
    • 醫療設備廠商
    • 學術機構
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭趨勢

  • 企業簡介
    • Charles River
    • Envigo
    • ICON PLC
    • IQVIA
    • LabCorp
    • MeDPace Holdings
    • MPI Research
    • PAREXEL
    • PPD
    • PRA Health Sciences
    • SGS
    • Syneos Health
    • WuXi Pharmatech

第7章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 60461

Contract research organizations provide support to the pharmaceutical, biotechnology, and medical device industries. The market growth can be attributed to the growing R&D expenditure, increased outsourcing of R&D activities, and a rising number of clinical trials. Efficiency is being considered as the most important factor in light of the financial burden faced by pharmaceutical companies from all directions. Patent expiries leading to generic rivalry and stringent demands from regulators continue to have an impact on the bottom lines of pharmaceutical companies.

Though the spending on R&D was reduced after several years, it is now growing yet again. According to the American pharmaceutical review, the involvement of CRO engagement at each clinical phase has also increased, and the pharmaceutical and biotechnology companies are banking more heavily on contracting out for the early stages of clinical research, from drug discovery through Phases I and II. Now, nearly two-thirds (63%) of the companies are appointing contract development and manufacturing organizations (CDMOs) and CROs for Phase II studies. This strong trend of outsourcing may lead to the growth of the contract research organization market. However, the COVID-19 pandemic may pose some serious challenges to the market over the forecast period.

Key Market Trends

Early-Phase Development Services Segment is Poised to Witness Robust Growth over the Forecast Period

With a growing number of patents expiring, the competition from generic counterparts of drugs is increasing and drug makers are under pressure to replace the revenue loss due to generics. Furthermore, R&D costs are increasing due to the complexity of drug molecules and more stringent regulatory requirements. Drug discovery and development processes are becoming increasingly complex. To counter this complexity and streamline the operations, pharmaceutical firms are outsourcing early drug development processes. Additionally, leading CROs have developed significant expertise in the field of early-phase development, and CROs are leveraging this expertise to offer highly efficient and accurate early-phase development services. CROs are also allowing small- and mid-size firms to enter the complex drug development process without significant investment in capital equipment. Pertaining to these reasons, the early-phase development services segment is poised to register robust growth rates.

Asia-Pacific is Expected to Record Fastest Growth over the Forecast Period

Pricing pressure due to the changing reimbursement scenario and generic competition is causing major pharmaceutical firms to outsource R&D and clinical trials, which is supplementing the growth of CRO services in the Asia-Pacific region. In the emerging countries of the region, the cost of conducting clinical trials is relatively cheaper, due to fewer labor costs and low costs for handling clinical trial supplies. The cost is around 40-60% lesser in the emerging countries, as compared to the cost in developed countries, such as the United States, Germany, and the United Kingdom. The low cost and the presence of major contract research organizations are fueling the market growth in the Asia-Pacific region.

Competitive Landscape

Globally, few major players control a major share of the market. However, the remaining market share is heavily fragmented with the presence of several local and niche players. Companies, like IQVIA, ICON PLC, and PPD, lead the contract research organization market. The major players in the market accumulated a huge amount of data, which is being employed to attain a competitive edge in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Research and Development Activities by Biopharmaceutical Companies
    • 4.2.2 Increasing Number of Clinical Trials
    • 4.2.3 Growing Trend of Outsourcing and Cost Savings Enabled by Using CRO Services
  • 4.3 Market Restraints
    • 4.3.1 Shortage of Skilled Professionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Service Type
    • 5.1.1 Clinical Research Services
      • 5.1.1.1 Phase I Clinical Research Services
      • 5.1.1.2 Phase II Clinical Research Services
      • 5.1.1.3 Phase III Clinical Research Services
      • 5.1.1.4 Phase IV Clinical Research Services
    • 5.1.2 Early-phase Development Services
    • 5.1.3 Laboratory Services
    • 5.1.4 Consulting Services
  • 5.2 By Therapeutic Area
    • 5.2.1 Oncology
    • 5.2.2 Infectious Diseases
    • 5.2.3 Central Nervous System (CNS) Disorders
    • 5.2.4 Immunological Disorders
    • 5.2.5 Cardiovascular Diseases
    • 5.2.6 Respiratory Disorders
    • 5.2.7 Diabetes
    • 5.2.8 Other Therapeutic Areas
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biopharmaceutical Companies
    • 5.3.2 Medical Device Companies
    • 5.3.3 Academic Institutes
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Charles River
    • 6.1.2 Envigo
    • 6.1.3 ICON PLC
    • 6.1.4 IQVIA
    • 6.1.5 LabCorp
    • 6.1.6 MeDPace Holdings
    • 6.1.7 MPI Research
    • 6.1.8 Parexel International
    • 6.1.9 PPD
    • 6.1.10 PRA Health Sciences
    • 6.1.11 SGS
    • 6.1.12 Syneos Health
    • 6.1.13 WuXi Pharmatech

7 MARKET OPPORTUNITIES AND FUTURE TRENDS